Protein Tyrosyl Phosphatase-1B Is Expressed by Normal Human Epidermis, Keratinocytes, and A-431 Cells and Dephosphorylates Substrates of the Epidermal Growth Factor Receptor

Gunaratne, Prabha; Stoscheck, Christa M.; Gates, Robert J.; Li, Liying; Nanney, Lillian B.; King, Lloyd E.

doi:10.1111/1523-1747.ep12398566

Cited by 8 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…48 Intense research over the last decade by us and others has shown PTP1B negatively regulates insulin and leptin signaling and sensitivity, as a phosphatase of insulin receptor and leptin receptor-associated kinase JAK2. 49–51 Though a role for PTP1B in DFU has not been reported, PTP1B is abundantly expressed in many cell types and tissues affected by DFU, namely neurons, 50 skin, 52 vascular smooth muscle 53 and endothelial progenitor cells. 54 Beyond regulating insulin and leptin, PTP1B plays a detrimental role in the signaling regulation of a broad network of growth factors that mediate wound healing, including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), nerve growth factor (NGF), and TGFβ, among others.…”

Section: Current Research Goalsmentioning

confidence: 99%

Emerging drugs for the treatment of diabetic ulcers

Tecilazich

Dinh

Veves

2013

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Introduction Diabetic ulcers are chronic non-healing ulcerations that despite the available medical tools still result in high amputation rates. Growing evidence suggests that alteration of the biochemical milieu of the chronic wound plays a significant role in diabetic wound healing impairment. Areas covered The basic pathophysiology and the conventional treatment strategy of diabetic foot ulcers have been reviewed in the first section. In the second part we describe the most up-to-date bench and translational research in the field. The third section focuses on the drugs currently under development and the ongoing clinical trials evaluating their safety and efficacy. Finally, we analyze the major drug development issues and the possible scientific approaches to overcome them. Expert opinion Significant strides in understanding the chronic wound development have led to the development of topical therapies to address aberrant expression of growth factors and overexpression of inflammatory cytokines. Current research in our lab suggests that in while decreased growth factor expression occurs at the local wound level, increased systemic serum levels of growth factors suggest growth factor resistance.

show abstract